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Abstract The generation of ceramides by the action of acidic 
and/or neutral sphingomyelinases has been implicated in many 
forms of apoptosis. We investigated whether exposure to 
ceramides is sufficient to induce apoptosis in human leukemia 
cells and, if so, what the characteristics of this form of apoptosis 
might be. Treatment of the acute lymphoblastic T-cell line CEM-
C7H2 with short- and medium-chain ceramide analogs (C2-, 
C6-, and C8-ceramide) resulted in apoptosis, whereas the inactive 
C2-dihydroceramide had no effect on cell survival. Induction of 
apoptosis was relatively slow (~40% after 24 h) and required 
high concentrations of ceramide analogs (40-100 μΜ). To 
investigate a possible involvement of interleukin Ι-β-converting 
enzyme (ICE) or ICE-related proteases, we treated CEM-C7H2 
sublines constitutively expressing the vaccinia virus protease 
inhibitor crmA with ceramide analogs. Although such cells were 
completely resistant to apoptosis induced by antibodies to the 
Apo-1/Fas surface receptor (a form of apoptosis known to be 
inhibitable by CrmA), they were not protected from ceramide-
induced cell death. In contrast, tetracycline-regulated over-
expression of Bcl-2 protected CEM-C7H2 sublines stably 
transfected with corresponding constructs from ceramide-induced 
apoptosis. Thus, in these human leukemia cells, ceramides induce 
a relatively slow death response that can be prevented by Bcl-2, 
but is independent of CrmA-inhibitable proteases. These 
characteristics distinguish ceramide-induced from other forms 
of apoptosis, such as Apo-1/Fas-induced cell death where 
ceramide production has been causally implicated. 
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1. Introduction 
Programmed cell death (apoptosis) has been recognized as 
an essential mechanism by which multicellular organisms dis-
pose of unnecessary or potentially harmful cells (reviewed in) 
[1-4]. An increasing number of genes contributing to, or pro-
tecting from, apoptosis induction has been identified, and nu-
merous laboratories are dedicated to the study of signal trans-
duction pathways by which the various apoptosis inducers 
lead to ultimate cell death. Analyses of programmed cell death 
in C. elegans have identified two crucial genes (reviewed in 
[5]). First, ced-9 and its mammalian homolog, bcl-2, that pre-
vent apoptosis in many systems by poorly understood mech-
anisms (reviewed in [6,7]). Second, ced-3 that is homologous 
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to proteases of the interleukin-lß-converting enzyme (ICE) 
family. These molecules are thought to mediate the terminal 
effector phase of most, if not all, forms of apoptosis by cleav-
ing proteins essential for cell survival [8]. 
Elevation of ceramides has been observed in many different 
forms of apoptosis (reviewed in [9-15]), a phenomenon attrib-
uted to the action of primarily neutral sphingomyelinases that 
become activated during apoptosis and liberate ceramide from 
membrane lipid sphingomyelin [13]. Elevation of ceramide 
may activate ceramide-dependent phosphatase [16] or kinase 
[17]. Other possible targets include some protein kinase C 
isoforms [18] and members of the mitogen-activated protein 
(MAP) kinases [19] which, in turn, may pass on the death 
signal. Moreover, treatment of various cells with ceramide 
analogs carrying short- or medium-sized fatty acid chains 
are sufficient to induce apoptosis (see above reviews). These 
results suggest a causal role of ceramide generation in many 
forms of apoptosis, such as that triggered by activation of the 
Apo-1/fas surface receptor [15,20,21]. 
Our laboratory has been studying different forms of apop-
tosis in the human acute T-cell leukemia model CCRF-CEM 
[22], including cell death induced by glucocorticoids, antibod-
ies to Apo-1/Fas, DNA-damaging agents and others [23-26]. 
Since ceramide has been implicated as a second messenger in 
several of these responses (see above), we analysed the effect 
of direct ceramide application in our system. In the human 
acute lymphoblastic cell line CEM-C7H2, ceramide analogs 
induced a relatively slow apoptotic response (~40% apopto-
tic cells 24 h after initiation of treatment) that required high 
concentrations of ceramide analogs (40-100 μΜ). Ceramide-
induced cell death could not be prevented by the vaccinia 
virus protease inhibitor crmA, while overexpression of Bcl-2 
protected CEM-C7H2 cells from this form of apoptosis. In 
conclusion, our study represents a first characterization of 
ceramide-induced apoptosis in the widely-used CCRF-CEM 
human leukemia model and, as discussed below, provides evi-
dence against the proposed causal role of ceramides in Apo-1/ 
Fas-induced apoptosis [27]. 
2. Material and methods 
2.1. Cell lines and cell culture 
The GC-sensitive cell line CEM-C7H2 [23], a subclone of the 
CCRF-CEM-C7 line [22], crmA-transfected CEM-C7H2 subclones 
2E8, 2G10 and 2H10 [26], and cell line CEM-C7H2-9F3 expressing 
transgenic bcl-2 under the control of a tetracycline responsive promo-
ter [28] have been described. In brief, crmA-expressing lines 2E8, 
2G10, and 2H10 were produced by transfecting CEM-C7H2 with a 
construct containing crmA cDNA driven by a ß-actin promoter [29]. 
For generation of bcl-2-expressing cell lines, CEM-C7H2 cells were 
first stably transfected with a construct constitutively expressing a 
tetracycline repressor — herpes simplex VP16 transactivator fusion 
protein (tTA) [30] from a human elongation factor la (EF-1) promo-
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ter. tTA-expressing CEM-C7H2 were subsequently stably transfected 
with a construct expressing bcl-2 cDNA [31] under the control of a 
tTA-responsive fusion promoter. The production of the sublines ex-
pressing crmA under the control of the human EF-1 promoter will be 
detailed below. All cell lines were grown in 5% CO2, saturated hu-
midity, at 37°C in RPMI-1640 supplemented with 10% bovine calf 
serum (HyClone, Logan, UT), 100 U/ml penicillin, 100 μ^ιηΐ strepto-
mycin, and 2 mM L-glutamine. 
2.2. Generation of CEM-C7H2 subclones expressing crmA under the 
control of the EF-1 promoter 
Plasmid pEFl-crmA was generated by PCR amplification of crmA 
cDNA from pHD1.2 [29] using primers ON361 (5'-TATGAATTCAC-
CA TCGATATCTTCAGGGAAATCG-3') and 362 (5'-ACTTA¿-
G^rCCTTAATTAGTTGTTGGAGAGCAATATC-3'). ON361 in-
troduced a partial Kozak translation consensus sequence 
(underlined) and EcoRl and Ncol restriction sites (italics), while 
ON362 introduced a BgM restriction site (italics). After amplification 
and purification, the DNA fragment was digested using EcoRl and 
Bglil resriction enzymes and subcloned into the EcoRl and BamHI 
sites of pKS+ (Stratagene, La Jolla, CA) to generate pKS-crmA. 
CrmA was then released from pKS by digestion with EcoRl and 
Notl followed by subcloning into the EcoRl and Noil sites of the 
expression vector pEFl-Neo (kindly provided by G. Baier, Innsbruck, 
Austria). For stable transfections, logarithmically growing CEM-
C7H2 cells were washed in PBS, pelleted at 300 Xg and resuspended 
at a density of 1X107 cells/400 μΐ PBS. Cells were mixed with 20 μg of 
either pSTneoB (the empty ß-actin promoter-based expression vector), 
pEFl-crmA, or pEFl-Neo, incubated for 10 min on ice, and electro-
porated (Biorad Lab., Vienna, Austria) at 500 uF and 300 V. There-
after, cells were again placed on ice for 10 min, diluted in 20 ml of 
growth medium and seeded on 96-well flat-bottom plates. Selection of 
stably transfected cells was initiated 48 h after electroporation using 
1 mg/ml G418 (bioactivity 70%). G418-resistant clones were cultured 
and frozen in liquid nitrogen for further analyses. 
2.3. Reagents, induction and analysis of apoptosis 
All reagents were from Sigma (Vienna, Austria) unless otherwise 
indicated. To study induction of apoptosis through Apol/fas, 2X105 
cells/ml were cultured with 0.1 μg/ml mouse monoclonal IgM anti-
body to Apol/fas (Immunotech, Marseille, France; clone CH11) or 
an isotype-matched control monoclonal for 6 h. Ceramides (Calbio-
chem, La Jolla, CA) were dissolved in DMSO (5 mg/ml) and used in 
final concentrations of 50 and 100 μΜ for C2-, C6-, and C2-dihydro-
ceramide (iV-acetyl,iV-hexoyl,iV-acetyldihydrosphingosine, respec-
tively), and 10 and 80 μΜ for C8-ceramide (iV-octoylsphingosine) 
for 6-48 h. Degree of apoptosis was determined as previously detailed 
[23]. Briefly, 2.5 X105 cells/ml were cultured in the presence or absence 
of apoptosis-inducing substances in 24-well flat-bottom plates for the 
indicated time, lysed with Triton X-100, stained with propidium io-
dide, and fluorescence determined by flow cytometry (FACScan, Bee-
ton Dickinson, Mountain View, CA). 
3. Results and discussion 
To investigate whether ceramides can induce apoptosis in 
human lymphoblastic leukemia cells, CEM-C7H2 were treat-
ed with ceramide analogs at various concentrations over 6-48 
h. Apoptosis was induced using 50-100 μΜ C2-, C6-, and C8-
ceramide, whereas 100 μΜ C2-dihydroceramide, used as an 
ineffective control substance, had no effect on cell survival. 
Fig. 1 shows a representative experiment using 50 μΜ C2-
ceramide and 100 μΜ C2-dihydroceramide as controls. After 
incubation of CEM-C7H2 cells with 50 μΜ C2-ceramide, 
apoptosis was evident at around 24 h (~40%) and reached 
~ 7 0 % after 48 h. In contrast, cells incubated with 100 μΜ 
dihydroceramide did not differ from untreated cells (5-10% 
apoptosis). 
Ceramides have been implicated in various forms of apop-
tosis, including Apo-1/Fas-induced apoptosis (see Section 1). 
The latter has been demonstrated to depend on the activity of 
CEM-C7H2 
24 hrs 48hrs 
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Fluorescence Intensity 
Fig. 1. Representative example of flow cytometric apoptosis analysis 
of untreated CEM-C7H2 (top panel) or cells treated with 50 μΜ 
C2-ceramide (middle) or 100 μΜ C2-dihydroceramide as ineffective 
control (bottom) for 24 (a-c) and 48 (d-f) h. The percentages of 
apoptotic nuclei were 8, 40, 6, 4, 73, and 4%, for panels a,b,c,d,e 
and f, respectively. 
ICE and ICE-like proteases [26,32-34] that may be triggered 
in a cascade-like fashion by an Apo-1/Fas receptor-bound 
protease [35,36]. It is currently unclear whether ceramide pro-
duction contributes to, or results from, activation of this path-
way. To investigate whether ceramide-induced apoptosis de-
pends on the activity of ICE or ICE-like proteases, we treated 
CEM-C7H2 cell Unes stably transfected with the ICE inhibitor 
crmA with ceramides. In one set of cell lines (exemplified by 
line 2E8), crmA-cDNA was expressed from a chicken ß-actin 
promoter. In an additional transfected CEM-C7H2 subline 
(2C11), crmA was expressed from the human EF-1 promoter 
using a construct that also contained a partial Kozak consen-
sus sequence to optimize translational efficiency. As exempli-
fied in Fig. 2, crmA overexpression did not protect CEM-
C7H2 sublines from ceramide-induced apoptosis. Thus, 
crmA overexpressing sublines 2E8 and 2C11 underwent apop-
tosis with the same characteristics as two control Unes (stably 
transfected with the 'empty' plasmids STNeoB and pEF-1-
Neo, respectively) and the parental untransfected CEM-
C7H2 Une. 
To rule out the possibility that ceramide induced a long-
lasting activation of crmA-sensitive ICE-like proteases that 
would consume all protective crmA, we treated the crmA-ex-
pressing cell lines with 50 μΜ C2-ceramide (or the ineffective 
control substance dihydroceramide) for 24 h and added 100 
ng/ml anti-Apo-1/Fas antibody for an additional 8 h (Fig. 3). 
The anti-Apo-1/Fas antibody caused a marked increase in 
apoptosis in the parental CEM-C7H2 Une and in sublines 
stably transfected with control plasmids pStNeoB and pEF-
Neo, whereas crmA-transfected sublines (2E8 and 2C11) were 
completely protected from increased apoptosis caused by the 
antibody. The low level of apoptosis seen in 2E8 and 2C11 
cells treated with C2-ceramide and anti-Apo-1/Fas antibody 
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Fig. 2. Representative example of flow cytometric apoptosis analysis 
of parental CEM-C7H2, CEM-C7H2 sublines transfected with con-
structs expressing crmA-cDNA from a chicken ß-actin (2E8) or a 
human EF-1 (2C11) promoter, and corresponding control lines 
(transfected with the 'empty' vectors StNeoB and pEFl-Neo, respec-
tively). All cells were treated with 100 μΜ C2-ceramide (C2-Cer) or 
C2-düiydroceramide (DH-Cer) for ~ 24 h. The percentage of apop-
totic nuclei is indicated in each panel. 
was due to the crmA-independent effect of C2-ceramides, 
since cells treated with the ineffective control substance dihy-
droceramide and anti-Apo-1/Fas showed essentially no apop-
tosis. These data clearly showed that sufficient amounts of 
bioactive crmA were present after ceramide treatment to pro-
tect cells from anti-Apo-1/Fas-induced apoptosis. Thus, Apo-
l/Fas-induced apoptosis and ceramide-induced apoptosis trig-
ger different cell death pathways, the former depending on 
activation of crmA-sensitive ICE-like proteases and the latter 
not. 
To investigate whether ceramide-induced apoptosis of hu-
man leukemia cells is sensitive to bcl-2 expression, we incu-
bated the CEM-C7H2 subline 9F3 that expresses human bcl-2 
cDNA under the control of a tetracycline-regulated promoter 
with ceramide. As shown in Fig. 4, in the presence of the 
tetracycline analog doxycycline, i.e., when bcl-2 expression is 
repressed, ceramide induced significant apoptosis in 9F3 cells. 
However, in the absence of doxycycline, i.e., when transcrip-
tional repression is released and bcl-2 is expressed, ceramide-
triggered apoptosis was completely prevented. Thus, cera-
mide-induced apoptosis in these human leukemia cells occurs 
via a Bcl-2-sensitive pathway. 
In conclusion, our analyses provide the first characteriza-
tion of ceramide-induced apoptosis in a human T-cell lympho-
blastic leukemia Une. These features can now be compared to 
cell death induced by other means and may provide evidence 
against, or in support of, a role of ceramide generation in the 
respective types of apoptosis. One particularly interesting ex-
ample concerns Apo-l/Fas-induced apoptosis which has been 
associated with ceramide production in various cell types (see 
Section 1). Crosslinking of Apo-1/Fas or the related TNFoc 
receptor leads to rapid, macromolecule neosynthesis-inde-
pendent apoptosis. The cytosolic domains of both receptors 
share a homologous region, called death domain, that pre-
sumably associates with death domain-containing factors 
(e.g., FADD, TRADD, TRAF, and possibly others) thereby 
transducing the death signal [37]. In the effector phase, ICE-
like proteases appear to be critical. Thus, Apo-l/Fas-induced 
cell death is dependent on expression of crmA-inhibitable 
ICE-like proteases in human leukemia [26] and HeLa [32,33] 
cells, and ICE-deficient mice do not undergo Apo-1/Fas or 
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Fig. 3. Representative example of flow cytometric apoptosis analysis 
of parental CEM-C7H2, CEM-C7H2 sublines transfected with con-
structs expressing crmA-cDNA from a chicken ß-actin (2E8) or a 
human EF-1 (2C11) promoter, and corresponding control lines 
(transfected with the 'empty' vectors StNeoB and pEFl-Neo, respec-
tively). All cells were incubated with 50 μΜ C2-ceramide (C2-Cer, 
left panels) or C2-dihydroceramide (DH-Cer, right panels) and, after 
24 h, 100 ng anti-Apo-1/Fas antibody CHI 11 was added for an-
other 8 h. The percentage of apoptotic nuclei is indicated in each 
panel. 
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Fig. 4. Representative example of flow cytometric apoptosis analysis 
of CEM-C7H2-9F3 cells expressing bcl-2 under the control of a tet-
racycline-repressed promoter treated with 40 uM C8-ceramide for 
24 h. The top panel shows nuclei from cells treated with ceramide 
in the presence of 10 ng/ml doxycycline (bcl-2 expression repressed), 
the bottom panel those from cells treated with ceramide in the ab-
sence of doxycycline (bcl-2 expression induced). The percentages of 
apoptotic nuclei were 40% in the absence of Bcl-2 (+doxycycline) 
and 4.1% in the presence of Bcl-2 (—doxycycline). 
TNFoc-mediated apoptosis [34]. Based on these findings, the 
question arose as to whether ceramide generation is part of the 
death pathway in these forms of apoptosis, and if so, whether 
sphingomyelinase activation precedes the activation of ICE 
and other ICE-like proteases or occurs subsequent to, and 
perhaps as a consequence of, activation of these proteases. 
Recently, Cuvillier et al. have shown that the ceramide me-
tabolites sphingosine and sphingosine phosphate prevent both 
ceramide-induced and Apo-1/Fas-induced cell death in HL-60 
and U937 cells, suggesting a causal role of ceramide genera-
tion in Apo-1/Fas-mediated apoptosis [27]. On the other 
hand, Muzio et al. [35] and Boldin et al. [36] reported the 
cloning of two novel proteins with ICE-like protease activity, 
termed FLICE and MACH, respectively, that can associate 
with the death domain protein FADD. This interaction is 
thought to occur as a rapid consequence of Apo-1 /TNFoc 
treatment and may enable FADD to induce apoptosis by 
activation of ICE-proteases [38]. In this scenario, ceramide 
production, if involved in this pathway, appears downstream 
of ICE activation [39]. Our findings, however, show that cer-
amide-induced apoptosis occurs much slower than Apo-1/Fas-
mediated cell death and independent of ICE or other crmA-
inhibitable proteases. Taken together, these data argue against 
a critical role of ceramide production in Apo-1/Fas-induced 
apoptosis, at least in our system. 
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